MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.94 0.77

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.87

Max

4.06

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+10.39% upside

Dividendes

By Dow Jones

Prochains Résultats

17 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

312M

1.4B

Ouverture précédente

3.17

Clôture précédente

3.94

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 janv. 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12 janv. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 janv. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12 janv. 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 janv. 2026, 23:18 UTC

Acquisitions, Fusions, Rachats

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 janv. 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 janv. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12 janv. 2026, 21:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

12 janv. 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12 janv. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 janv. 2026, 20:54 UTC

Résultats

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 janv. 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 janv. 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 janv. 2026, 20:18 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 janv. 2026, 20:18 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 janv. 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 janv. 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 janv. 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 janv. 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 janv. 2026, 19:24 UTC

Acquisitions, Fusions, Rachats

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 janv. 2026, 19:22 UTC

Acquisitions, Fusions, Rachats

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 janv. 2026, 18:21 UTC

Acquisitions, Fusions, Rachats

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 janv. 2026, 18:20 UTC

Acquisitions, Fusions, Rachats

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 janv. 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 janv. 2026, 18:16 UTC

Market Talk
Acquisitions, Fusions, Rachats

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 janv. 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12 janv. 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 janv. 2026, 18:01 UTC

Acquisitions, Fusions, Rachats

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 janv. 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

10.39% hausse

Prévisions sur 12 Mois

Moyen 4.25 USD  10.39%

Haut 4.5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat